Zusammenfassung
Bronchospasmolytika werden zur Behandlung des Asthma bronchiale und der chronisch-obstruktiven Atemwegskrankheit (COPD) eingesetzt. Bei beiden Erkrankungen ist es das Ziel, die Bronchialobstruktion, die beim Asthma wesentlich reversibler ist als bei der COPD, zu beseitigen und das typische Spätstadium der COPD mit Ateminsuffizienz und Cor pulmonale so weit wie möglich zu bessern.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Agertoft L., Pedersen S. (2000): Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N. Engl. J. Med. 343: 1064–1069.
Arzneimittelkommission der deutschen Ärzteschaft (2003): Arzneiverordnungen. 20. Aufl., Deutscher Ärzte-Verlag, Köln, S. 610.
Arzneiverordnung in der Praxis (AVP) (2001): Asthma bronchiale, Sonderheft 1. Auflage, September 2001.
Barnes PJ. (1995): Beta-adrenergic receptors and their regulation. Am. J. Respir. Crit. Care Med. 152: 838–860.
Barnes P.J., Pauwels R.A. (1994): Theophylline in the management of asthma: time for reappraisal? Eur. Respir. J. 7: 579–591.
Bundesamt für Arzneimittel und Medizinprodukte (BfArM) (1998): Arzneimittel mit problematischer Bioverfügbarkeit. 9. Bekanntmachnung gemäß § 26, Abs. 3 AMG vom 19.1.1998.
Brocklebank D., Wright J., Cates Ch. (2001): Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. Brit. Med. J. 323: 1–7.
Buhl R., Kardos P., Magnussen H., Matthys H., Sauer R., Schauer P. et al. (1999): Feste Kombination inhalierbarer Kortikoide und langwirkender ß2-Sympathomimetika zur Langzeittherapie des Asthma bronchiale. Pneumologie 53: 210–212.
Busse W.W., Brazinsky S., Jacobson K., Stricker W., Schmitt K., Vanden Bürgt J. et al. (1999): Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new prolellant. J. Allergy Clin. Immunol. 104: 1215–1222.
Clarke P.S., Ratowsky D.A. (1990): Effect of fenoterol hydrobromide and sodium cromoglycate individually and in combination on postexercise asthma. Ann. Allergy 64(2 Pt. 2): 187–190.
Crout J.R. (1974): Fixed combination prescription drugs: FDA policy. J. Clin. Pharmacol. 14: 249–254.
Debelic M., Hertel G., König J. (1988): Double-blind crossover study comparing sodium cromoglycate, reproterol, reproterol plus sodium cromoglycate, and placebo in exercise-induced asthma. Ann. Allergy 61: 25–29.
Drazen J.M., Israel E., O’Byrne P.M. (1999): Treatment of asthma with drugs modifying the leukotrien pathway. N. Engl. J. Med. 340: 197–206.
Ducharme F.M., Hicks G.C. (2001): Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma. The Cochrane Library, Issue 2. Oxford: Update Software.
Gehrke I., Böhm E., Sybrecht G.W. (1986): Stress-induced asthma — placebo-controlled double-blind comparison of prevention using fenoterol, disodium cromoglycate and a combination of the two. Prax. Klin. Pneumol. 40: 129–134.
Global Initiative for Chronic Obstructive Lung Disease (GOLD 2001) (2001): http://www.goldcopd.com/workshop/html.
Grahnén A., Eckernas S.A., Brundin R.M., Ling-Andersson A. (1994): An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br. J. Clin. Pharmacol. 38: 521–525.
Hanania N.A., Chapman K.R., Sturtridge W.C. et al. (1995): Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J. Allergy Clin. Immunol. 96: 571–579.
Jarvis B., Markham A. (2000): Montelukast — a review of its therapeutic potential in persistent asthma. Drugs 59: 891–928.
Leitlinien COPD (2002): http://www.leitlinien.de/themen/infocopd.htm.
Leach C, Davidson P.J., Boudreau RJ. (1998): Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFCbeclomethasone. Eur. Respir. J. 12: 1346–1353.
Lemmer B. (1990): Chronopharmakologische Aspekte der Theophyllintherapie. In: Blume H. (Hrsg.): Bioäquivalenz retardierter Theophyllin-Fertigarzneimittel. Govi, Frankfurt, S. 75–82.
Lemmer B., Wettengel R. (2001): Erkrankungen der Atemwege. In: Lemmer B., Brune K. (Hrsg.): Pharmakotherapie — Klinische Pharmakologie. 11. Aufl., Urban & Fischer Verlag, München, S. 313–329.
Lipworth B.J. (1999): Modern drug treatment of chronic asthma. Brit. Med. J. 318: 380–383.
Markham A., Jarvis B. (2000): Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 60:1207–1233.
McCowan C, Neville R.G., Thomas G.E., Crombie I.K., Clark R.A. et al. (1998): Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland. Brit. Med. J. 316: 668–672.
National Heart, Lung, and Blood Institute (1997): Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma [EPR-2]. National Institutes of Health, pub. no. 97–4051.
Parfitt K. (1999): Martindale. The complete drug reference. 32nd ed. Pharmaceutical Press, London, pp. 765–774.
Robinson D.S., Campbell D., Barnes P.J. (2001): Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebocontrolled trial. Lancet 357: 2007–2011.
Rodrigo G., Rodrigo C, Burschtin O. (1999): A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am. J. Med. 107: 363–370.
Schmidt H. (1994): Retardtheophyllin ist nicht gleich Retardtheophyllin. Atemwegs Lungenkr. 20: 223–231.
Sears M.R., Rea H.H., Fenwick J. et al. (1987): 75 Deaths in asthmatics prescibed home nebulisers. Brit. Med. J. 294: 477–480.
Serafín W.E. (1996): Drugs used in the treatment of asthma. In: Hardman J.H., Limbird L.E., Molinoff P. B., Ruddon R.W., Goodman Gilman A. (eds.): Goodman & Gilman The Pharmacological Basis of Therapeutics, 9th ed. McGraw Hill, New York, pp. 659–682.
Smolensky M.H., D’Alonso G.E. (1997): Progress in the chronotherapy of nocturnal asthma. In: Redfern P., Lemmer B. (eds.): Physiology and Pharmacology of Biological Rhythms. Handbook of Experimental Pharmacology, Vol. 125, Springer, Berlin, Heidelberg, New York, pp. 205–249.
The Childhood Asthma Management Program Research Group (2000): Long-term effects of budesonide or nedocromil in children with asthma. N. Engl. J. Med. 343: 1054–1063.
Weinberger M., Hendeles L. (1996): Theophylline in asthma. N. Engl. J. Med. 334: 1380–1388.
Wettengel R., Berdel D., Hofmann D., et al. (1998): Asthmatherapie bei Kindern und Erwachsenen. Empfehlungen der Deutschen Atemwegsliga in der Deutschen Gesellschaft für Pneumologie. Med. Klinik 93: 639–650.
Williams M.H. (1989): Increasing severity of asthma from 1960 to 1987. N. Engl. J. Med. 320:1015–1020.
Wilson A.M, Lipworth B.J., (1999): 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax 54: 20–26.
Wohl M.E. B., Majzoub J.A. (2000): Asthma, steroids, and growth. N. Engl. J. Med. 343: 1113–1114.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lemmer, B. (2004). Bronchospasmolytika und Antiasthmatika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2003. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18512-0_19
Download citation
DOI: https://doi.org/10.1007/978-3-642-18512-0_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-40188-9
Online ISBN: 978-3-642-18512-0
eBook Packages: Springer Book Archive